ACE Inhibitors for the Treatment of Hypertension Drug Selection by Means of the SOJA Method
In this article the ACE inhibitors available in the United Kingdom (UK) are scored by means of the SOJA method. The System of Objectified Judgement Analysis (SOJA) method is a model for rational drug selection. The relevant selection criteria for a certain group of drugs are defined and judged by a panel of experts and each selection criterion is given a relative weight. The more important that a selection criterion is considered, the higher the relative weight that is given to that criterion. The ideal properties for each selection criterion are determined and each drug is scored as a percentage of the score of the ideal drug for all selection criteria. The following selection criteria were used (relative weight): number of formulations (20), number of indications (20), variation in bioavailability (40), interactions (40), trough/peak ratio diastolic blood pressure lowering effect (20), efficacy (250), side-effects (150), dosage frequency (100), documentation (100) and effect on clinical endpoints (260). Ramipril showed the highest score, followed by perindopril, lisinopril and enalapril. The well documented effects on clinically relevant end points, such as cardiovascular morbidity and mortality contributed to the high score for ramipril.
Keywords: ACE inhibitors; ASCOT-BPLA; Captopril; Cilazapril; Enalapril; Fosinopril; Gopten; Imidapril; Lisinopril; Moexipril; Perdix; Perindopril; Pharmacokinetics; Quinapril; Ramipril; SOJA method; SOLVD; Staril; Tanatril; Trandolapril; Vascase; drug selection; hypertension
Document Type: Research Article
Publication date: 01 January 2011
- Reviews on Recent Clinical Trials publishes frontier reviews on recent clinical trials of major importance. The journal's aim is to publish the highest quality review articles in the field. Topics covered include: important Phase I - IV clinical trial studies, clinical investigations at all stages of development and therapeutics.
The journal is essential reading for all researchers and clinicians involved in drug therapy and clinical trials.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites